NicOx : Garufi ... e la Rivoluzione Pharma (9 lettori)
- Creatore Discussione Yesod
- Data di Inizio
- Stato
DickSIM
Prima o poi....ci becco!
FDA throws up roadblock for Takeda's diabetes drug
June 29, 2009 — 10:09am ET
Takeda confirmed today that the FDA won't approve its critically important diabetes drug alogliptin without a new clinical trial that fully explores the drug's cardiovascular effects. A spokesman for the company told Bloomberg that the application for the Type 2 diabetes therapy could be resubmitted in two years, after a new trial is completed.
While a number of analysts had predicted a lengthy delay, noting the agency's new and tougher safety standards for diabetes drugs, the decision was a heavy blow for Takeda. The Japanese company had hoped to start marketing the once daily alogliptin, or SYR-322, as its existing drug, Actos, lost patent protection. Earlier this month Takeda announced that it was delaying its European application for alogliptin as it pursues new studies. A new application for Europe is expected in 2012.
"SYR-322 is the most important drug development agenda for Takeda," company spokesman Hisashi Tokinoya told Bloomberg. "We expect to lose patent protection on Actos, and with the decision by the FDA it's difficult to have the drug in time for the patent expiration.
------------------------
doc .......mi sembra EASY!
che si torna sempre li.......... CARDIOVASCULAR SAFETY!
June 29, 2009 — 10:09am ET
Takeda confirmed today that the FDA won't approve its critically important diabetes drug alogliptin without a new clinical trial that fully explores the drug's cardiovascular effects. A spokesman for the company told Bloomberg that the application for the Type 2 diabetes therapy could be resubmitted in two years, after a new trial is completed.
While a number of analysts had predicted a lengthy delay, noting the agency's new and tougher safety standards for diabetes drugs, the decision was a heavy blow for Takeda. The Japanese company had hoped to start marketing the once daily alogliptin, or SYR-322, as its existing drug, Actos, lost patent protection. Earlier this month Takeda announced that it was delaying its European application for alogliptin as it pursues new studies. A new application for Europe is expected in 2012.
"SYR-322 is the most important drug development agenda for Takeda," company spokesman Hisashi Tokinoya told Bloomberg. "We expect to lose patent protection on Actos, and with the decision by the FDA it's difficult to have the drug in time for the patent expiration.
------------------------
doc .......mi sembra EASY!
che si torna sempre li.......... CARDIOVASCULAR SAFETY!
Netzach
Forumer storico
ho fatto una toccata e fuga di 1gg e mezzo praticamente e visto che sei inqazzato con il doc ( e adesso pure con me
ps: quando sei venuto su dalle mie parti e non ti sei fatto sentire non ti ho mica mandato a fare in culo e non ti ho nemmeno tolto il saluto....
tu a quanto pare si....scelta tua!
pss : a luglio se scendo ancora e sei disponibile
mi tocca sdoppiarmi e mi devo prendere pure le parole!!
[/quote
Dove si mangia dove si beveio sarò sempre presente
Non mangio con te nè ora nè in futuro ... FOTTITI DOCTOR-NO ... hai superato ogni limite ormai da troppo tempo.
PS = ieri sera, pescati 30 Kg di polpi ...
doctor NO
NO nel DNA
tu sei già fottuto solo ad esisterei polpi sono cibo per i robinson crusoe
meglio una pizza in compagnia che 30 kg di polpo in to o culu
io pranzo con i nicoxxiani e tu
doctor NO
NO nel DNA
FDA throws up roadblock for Takeda's diabetes drug
June 29, 2009 — 10:09am ET
Takeda confirmed today that the FDA won't approve its critically important diabetes drug alogliptin without a new clinical trial that fully explores the drug's cardiovascular effects. A spokesman for the company told Bloomberg that the application for the Type 2 diabetes therapy could be resubmitted in two years, after a new trial is completed.
While a number of analysts had predicted a lengthy delay, noting the agency's new and tougher safety standards for diabetes drugs, the decision was a heavy blow for Takeda. The Japanese company had hoped to start marketing the once daily alogliptin, or SYR-322, as its existing drug, Actos, lost patent protection. Earlier this month Takeda announced that it was delaying its European application for alogliptin as it pursues new studies. A new application for Europe is expected in 2012.
"SYR-322 is the most important drug development agenda for Takeda," company spokesman Hisashi Tokinoya told Bloomberg. "We expect to lose patent protection on Actos, and with the decision by the FDA it's difficult to have the drug in time for the patent expiration.
------------------------
doc .......mi sembra EASY!
che si torna sempre li.......... CARDIOVASCULAR SAFETY!
ola Dick el pullaster è nervoso
non pesca i polipassi per il trio vorrà dire che panzeremo ad aragoste e champagne senza el nino
Netzach
Forumer storico
ola Dick el pullaster è nervoso
Fottiti di nuovo ...
La compagnia me la scelgo ...
Vai a fare lo sborrone con chi vuoi ...
Preferisco essere Robinson Crosuè, piuttosto che un pallonaro ed imbonitore come te.
La realtà dei fatti è quella che conta e tu non accetti alcuna altra posizione se non la tua e chi non la pensa come te è uno sfigato, secondo te e quindi ti senti inappropriatamente autorizzato a sfotterlo ...
Per me resti uno sfigato incapace di ascoltare e rispettare opinioni diverse dalle tue, pur mantenendo la tua posizione ...
E' facile in pratica, ma tu non puoi vivere senza rompere i c.oglioni a qualcuno ... ormai è più forte di te ...
Ultima modifica:
doctor NO
NO nel DNA
doctor NO
NO nel DNA
Per i festeggiamenti ho già la rubrica piena e l'imbarazzo della scelta
Quando vuoi sei il benvenuto:vicini::vicini::vicini::vicini::vicini::vicini::vicini::vicini::vicini::vicini::vicini: non fare più il cattivone
e piantala di cantartela e sonartela da solo
- Stato